Market Cap 2.33B
Revenue (ttm) 0.00
Net Income (ttm) -422.77M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,466,871
Avg Vol 1,973,026
Day's Range N/A - N/A
Shares Out 146.21M
Stochastic %K 52%
Beta 1.30
Analysts Strong Sell
Price Target $31.60

Company Profile

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; DNL343 eIF2B activator program for amyotrophic lateral sclerosis; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Synd...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 866 8547
Address:
161 Oyster Point Boulevard, South San Francisco, United States
DaBullRunMasta
DaBullRunMasta Oct. 27 at 6:37 PM
$OGN $DNLI Let's see where this goes, audits happen all the time. This is a no brainer!
0 · Reply
DaBullRunMasta
DaBullRunMasta Oct. 23 at 5:15 PM
$TAK $DNLI Keep an keen eye on! Market shake and bakers baby!
0 · Reply
DoctrBenway
DoctrBenway Oct. 22 at 1:44 PM
$DNLI Added 20% @ 16.9
0 · Reply
Drashkawisha
Drashkawisha Oct. 20 at 4:10 PM
$DNLI Think bigger than one PDUFA. This is about the revolutionary Blood-Brain Barrier platform tech. Unlocking treatments for Alzheimer's, Parkinson's & more. Huge potential unfolding. Patience = reward
0 · Reply
Quantum_Capital_LLC
Quantum_Capital_LLC Oct. 18 at 9:54 AM
$DNLI ready for end of year surge. Do your DD. Long term
0 · Reply
Drashkawisha
Drashkawisha Oct. 17 at 4:35 PM
$DNLI nice
0 · Reply
Drashkawisha
Drashkawisha Oct. 17 at 8:46 AM
$DNLI Classic risk-off day. The entire biotech sector ($XBI) is getting hit on macro inflation fears, not on fundamentals. This is the noise that shakes out weak hands. It doesn't change the clinical data, the unmet need, or the PDUFA dates for high-conviction plays. Using this manufactured fear as a discount to add to core positions. The thesis remains unchanged.
1 · Reply
NYG4ever
NYG4ever Oct. 16 at 5:01 PM
$VKTX for those looking for an example of short covering or a signal - ill use my recent position with $DNLI - again not a pump post just an example of what a major short position cover looks like. 2 mill shares pit of a total of 14 thats significant position closed.
1 · Reply
NYG4ever
NYG4ever Oct. 16 at 4:09 PM
$VKTX started a new position in $DNLI for those who want to know lol. 3k shares
1 · Reply
Drashkawisha
Drashkawisha Oct. 16 at 7:40 AM
$DNLI I told you all 💥💥💥
0 · Reply
Latest News on DNLI
The Best Small-Cap Stocks to Buy Now

Aug 12, 2025, 9:47 AM EDT - 2 months ago

The Best Small-Cap Stocks to Buy Now

KYMR WAY


Denali Therapeutics: Vast Pipeline, First Approval Up Ahead

Mar 20, 2025, 2:16 PM EDT - 7 months ago

Denali Therapeutics: Vast Pipeline, First Approval Up Ahead


Why Is Denali Therapeutics Stock Trading Higher On Wednesday?

Jan 15, 2025, 2:26 PM EST - 10 months ago

Why Is Denali Therapeutics Stock Trading Higher On Wednesday?


Denali Therapeutics ALS drug fails in mid-stage trial

Jan 6, 2025, 4:43 PM EST - 10 months ago

Denali Therapeutics ALS drug fails in mid-stage trial


Denali Has A Neurodegenerative Edge Despite Market Skepticism

Nov 16, 2024, 8:56 AM EST - 1 year ago

Denali Has A Neurodegenerative Edge Despite Market Skepticism


Denali's New Summit: Changing Hunter Syndrome Landscape

Oct 2, 2023, 5:26 AM EDT - 2 years ago

Denali's New Summit: Changing Hunter Syndrome Landscape


MPS II And Beyond: Implications Of Denali's Promising Pipeline

Jul 23, 2023, 12:51 AM EDT - 2 years ago

MPS II And Beyond: Implications Of Denali's Promising Pipeline


Denali: Need Patient Data To Justify That High Valuation

Jan 16, 2023, 12:15 PM EST - 3 years ago

Denali: Need Patient Data To Justify That High Valuation


DaBullRunMasta
DaBullRunMasta Oct. 27 at 6:37 PM
$OGN $DNLI Let's see where this goes, audits happen all the time. This is a no brainer!
0 · Reply
DaBullRunMasta
DaBullRunMasta Oct. 23 at 5:15 PM
$TAK $DNLI Keep an keen eye on! Market shake and bakers baby!
0 · Reply
DoctrBenway
DoctrBenway Oct. 22 at 1:44 PM
$DNLI Added 20% @ 16.9
0 · Reply
Drashkawisha
Drashkawisha Oct. 20 at 4:10 PM
$DNLI Think bigger than one PDUFA. This is about the revolutionary Blood-Brain Barrier platform tech. Unlocking treatments for Alzheimer's, Parkinson's & more. Huge potential unfolding. Patience = reward
0 · Reply
Quantum_Capital_LLC
Quantum_Capital_LLC Oct. 18 at 9:54 AM
$DNLI ready for end of year surge. Do your DD. Long term
0 · Reply
Drashkawisha
Drashkawisha Oct. 17 at 4:35 PM
$DNLI nice
0 · Reply
Drashkawisha
Drashkawisha Oct. 17 at 8:46 AM
$DNLI Classic risk-off day. The entire biotech sector ($XBI) is getting hit on macro inflation fears, not on fundamentals. This is the noise that shakes out weak hands. It doesn't change the clinical data, the unmet need, or the PDUFA dates for high-conviction plays. Using this manufactured fear as a discount to add to core positions. The thesis remains unchanged.
1 · Reply
NYG4ever
NYG4ever Oct. 16 at 5:01 PM
$VKTX for those looking for an example of short covering or a signal - ill use my recent position with $DNLI - again not a pump post just an example of what a major short position cover looks like. 2 mill shares pit of a total of 14 thats significant position closed.
1 · Reply
NYG4ever
NYG4ever Oct. 16 at 4:09 PM
$VKTX started a new position in $DNLI for those who want to know lol. 3k shares
1 · Reply
Drashkawisha
Drashkawisha Oct. 16 at 7:40 AM
$DNLI I told you all 💥💥💥
0 · Reply
tic2tape
tic2tape Oct. 14 at 7:59 PM
$DNLI what does the molecular weighting issue mean for the trials? For kin biotech dude here. Thanks
1 · Reply
Drashkawisha
Drashkawisha Oct. 14 at 6:57 PM
$DNLI you see... no drama...
0 · Reply
DoctrBenway
DoctrBenway Oct. 14 at 3:37 PM
$DNLI 4 month delay on PDUFA puts me into LTCG!
1 · Reply
TwongStocks
TwongStocks Oct. 14 at 1:04 PM
$DNLI Some added color on the delay. https://www.fiercebiotech.com/biotech/denalis-hunter-syndrome-drug-latest-be-hit-fda-decision-delay "In separate notes Monday evening, analysts with William Blair and Evercore ISI wrote that the delay came after Denali flagged an incorrect molecular weight for the drug shown on a public source. Because the FDA often uses such sources to inform its pharmacokinetic analyses, Denali "proactively" flagged the discrepancy, according to Evercore ISI's note, and the FDA responded by asking for "updated molecular weight info directly" from the biotech. “Management believes that, due to the nature that the discrepancy was identified late in the review cycle, procedurally it made sense for the agency to issue a major amendment, extending the PDUFA by three months,” the William Blair analysts wrote."
1 · Reply
ZacksResearch
ZacksResearch Oct. 14 at 12:40 PM
FDA delay for $DNLI's lead drug — a bump in the road or a buying opportunity? 🤔 The extended review timeline for tividenofusp alfa pushes the target date to April 2026, as Denali submits updated clinical pharmacology information. Despite this setback, no new efficacy or safety concerns were raised. Discover the implications for DNLI's pipeline here 👉 https://www.zacks.com/stock/news/2768081/fda-extends-review-of-dnlis-hunter-syndrome-drug-by-three-months?cid=sm-stocktwits-2-2768081-body-15868&ADID=SYND_STOCKTWITS_TWEET_2_2768081_BODY_15868
1 · Reply
ZacksResearch
ZacksResearch Oct. 14 at 11:40 AM
$DNLI hit with a setback — FDA pushes drug review to April 2026 ⚠️ The agency extended its review of Denali’s Hunter syndrome treatment, tividenofusp alfa, by three months — delaying a key approval milestone. Full details on the delay and what it means for DNLI’s path ahead 👉 https://www.zacks.com/stock/news/2768081/fda-extends-review-of-dnlis-hunter-syndrome-drug-by-three-months?cid=sm-stocktwits-2-2768081-teaser-15866&ADID=SYND_STOCKTWITS_TWEET_2_2768081_TEASER_15866
1 · Reply
Drashkawisha
Drashkawisha Oct. 14 at 6:53 AM
$DNLI Reading between the lines: This is a procedural, 3-month delay to April 5, not a clinical one. The FDA's request was for "updated clinical pharmacology information," with no red flags on efficacy or safety. This means the FDA is doing a deep, serious review of a revolutionary platform. The core thesis of validating the entire TV technology remains 100% intact. Holding my position strong
0 · Reply
Drashkawisha
Drashkawisha Oct. 14 at 5:25 AM
$DNLI The 3-month PDUFA date extension for $DNLI's tividenofusp alfa is a classic "buy the dip" opportunity for long-term investors. The delay to April 5, 2026, is purely technical due to the FDA classifying new information as a "Major Amendment"; it is not related to any concerns about the drug's safety or effectiveness. This is short-term noise creating a discount on a revolutionary platform technology. The market is overreacting to a procedural delay while ignoring the strong underlying science and the massive unmet need for a Hunter syndrome therapy that crosses the blood-brain barrier. I am holding my position and see this weakness as a gift.
0 · Reply
deucestwits
deucestwits Oct. 13 at 8:05 PM
$DNLI extended to April 5.
1 · Reply
DoctrBenway
DoctrBenway Oct. 13 at 8:05 PM
$DNLI We’ll lose some short-termers on this news, but I prefer to hold a while: https://investors.denalitherapeutics.com/node/11276/pdf
0 · Reply
Drashkawisha
Drashkawisha Oct. 13 at 1:45 PM
$DNLI looking strong. Tividenofusp (DNL310) has Jan 5, 2026 PDUFA with Priority Review. Data show durable CSF/urine HS reduction & good safety. Platform validates BBB delivery. $977M cash runway secured. If approved, could unlock premium rare disease pricing. Bullish setup.
0 · Reply
Estimize
Estimize Oct. 13 at 11:03 AM
Wall St is expecting -0.75 EPS for $DNLI Q3 [Reporting 10/30 AMC] http://www.estimize.com/intro/dnli?chart=historical&metric_name=eps&utm_c
0 · Reply